The purpose of this study was to evaluate the clinical impacts of ampicillin-susceptible but penicillin-resistant (ASPR) phenotypes of Enterococcus faecalis on clinical outcomes in patients with bloodstream infection (BSI). A total of 295 patients with an E. faecalis BSI from six sentinel hospitals during a 2-year period (from May 2016 to April 2018) were enrolled in this study. Putative risk factors, including host-, treatment-, and pathogen-related variables, were assessed to determine the associations with the 30-day mortality rate of patients with an E. faecalis BSI. The proportion of ASPR E. faecalis isolates was 22.7% (67/295). ASPR isolates (adjusted odds ratio, 2.27; 95% confidence interval, 1.01 to 5.02) exhibited a significant association with an increased 30-day mortality rate, and a significant difference in survival was identified in a group of patients treated with ampicillin- and/or piperacillin-based regimens who were stratified according to the penicillin susceptibility of the causative pathogen (P 0.011 by a log rank test). ASPR E. faecalis BSIs resulted in a 2-fold-higher 30-day mortality rate (26.9%; 18/67) than for the BSIs caused by penicillin-susceptible strains (12.3%; 28/228). The differences in mortality rates of patients stratified by penicillin susceptibility were likely due to the treatment failures of ampicillin and/or piperacillin in patients with an ASPR E. faecalis BSI.
Bibliographical noteFunding Information:
We thank Kor-GLASS participants for their contribution to the program. This study was supported by the research program funded by the Korea Centers for Disease Control and Prevention (number 2017E4400101). The funder of the study had no role in study design, data collection, data interpretation, or writing of the report. We do not have conflicts of interest to declare.
© 2019 American Society for Microbiology. All Rights Reserved.
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases